Indofarma Tbk
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutic… Read more
Indofarma Tbk (INAF) - Net Assets
Latest net assets as of September 2025: Rp-890.94 Billion IDR
Based on the latest financial reports, Indofarma Tbk (INAF) has net assets worth Rp-890.94 Billion IDR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp581.56 Billion) and total liabilities (Rp1.47 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp-890.94 Billion |
| % of Total Assets | -153.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | -365.85% |
| 10-Year Change | -293.02% |
| Growth Volatility | 213.14 |
Indofarma Tbk - Net Assets Trend (2000–2024)
This chart illustrates how Indofarma Tbk's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Indofarma Tbk (2000–2024)
The table below shows the annual net assets of Indofarma Tbk from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp-1.14 Trillion | -42.27% |
| 2023-12-31 | Rp-804.15 Billion | -1031.29% |
| 2022-12-31 | Rp86.35 Billion | -83.01% |
| 2021-12-31 | Rp508.31 Billion | +18.12% |
| 2020-12-31 | Rp430.33 Billion | -14.78% |
| 2019-12-31 | Rp504.94 Billion | +1.67% |
| 2018-12-31 | Rp496.65 Billion | -5.65% |
| 2017-12-31 | Rp526.41 Billion | -8.57% |
| 2016-12-31 | Rp575.76 Billion | -2.86% |
| 2015-12-31 | Rp592.71 Billion | +0.13% |
| 2014-12-31 | Rp591.96 Billion | +0.20% |
| 2013-12-31 | Rp590.79 Billion | -9.12% |
| 2012-12-31 | Rp650.10 Billion | +6.72% |
| 2011-12-31 | Rp609.19 Billion | +95.71% |
| 2010-12-31 | Rp311.27 Billion | +4.20% |
| 2009-12-31 | Rp298.72 Billion | +0.72% |
| 2008-12-31 | Rp296.60 Billion | +1.73% |
| 2007-12-31 | Rp291.56 Billion | +3.95% |
| 2006-12-31 | Rp280.49 Billion | +5.75% |
| 2005-12-31 | Rp265.25 Billion | +3.75% |
| 2004-12-31 | Rp255.67 Billion | -4.58% |
| 2003-12-31 | Rp267.94 Billion | -32.68% |
| 2002-12-31 | Rp397.99 Billion | -23.08% |
| 2001-12-31 | Rp517.44 Billion | +76.86% |
| 2000-12-31 | Rp292.57 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Indofarma Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1757.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rp309.93 Billion | % |
| Other Comprehensive Income | Rp210.97 Billion | % |
| Other Components | Rp81.12 Billion | % |
| Total Equity | Rp-1.14 Trillion | 100.00% |
Indofarma Tbk Competitors by Market Cap
The table below lists competitors of Indofarma Tbk ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TCI GENE Inc.
TWO:6879
|
$4.65 Million |
|
More Return Public Company Limited
BK:MORE
|
$4.65 Million |
|
Spenda Ltd
AU:SPX
|
$4.65 Million |
|
INTRASENSE SAS EO -05
F:I8S
|
$4.65 Million |
|
Carlo Rino Group Bhd
KLSE:0335
|
$4.64 Million |
|
Shah Alloys Limited
NSE:SHAHALLOYS
|
$4.64 Million |
|
Akora Resources Ltd
AU:AKO
|
$4.64 Million |
|
Stavely Minerals Ltd
AU:SVY
|
$4.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Indofarma Tbk's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -804,133,826,522 to -1,144,019,857,000, a change of -339,886,030,478.
- Net loss of 334,488,575,000 reduced equity.
- Other comprehensive income decreased equity by 5,397,455,392.
- Other factors decreased equity by 86.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp-334.49 Billion | -29.24% |
| Other Comprehensive Income | Rp-5.40 Billion | -0.47% |
| Other Changes | Rp-86.00 | -0.0% |
| Total Change | Rp- | % |
Book Value vs Market Value Analysis
This analysis compares Indofarma Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | Rp85.70 | Rp126.00 | x |
| 2006-12-31 | Rp90.55 | Rp126.00 | x |
| 2007-12-31 | Rp93.97 | Rp126.00 | x |
| 2008-12-31 | Rp95.70 | Rp126.00 | x |
| 2009-12-31 | Rp96.97 | Rp126.00 | x |
| 2010-12-31 | Rp100.48 | Rp126.00 | x |
| 2011-12-31 | Rp196.85 | Rp126.00 | x |
| 2012-12-31 | Rp209.82 | Rp126.00 | x |
| 2013-12-31 | Rp190.68 | Rp126.00 | x |
| 2014-12-31 | Rp191.00 | Rp126.00 | x |
| 2015-12-31 | Rp191.34 | Rp126.00 | x |
| 2016-12-31 | Rp185.66 | Rp126.00 | x |
| 2017-12-31 | Rp169.81 | Rp126.00 | x |
| 2018-12-31 | Rp160.21 | Rp126.00 | x |
| 2019-12-31 | Rp162.92 | Rp126.00 | x |
| 2020-12-31 | Rp138.85 | Rp126.00 | x |
| 2021-12-31 | Rp164.01 | Rp126.00 | x |
| 2022-12-31 | Rp27.86 | Rp126.00 | x |
| 2023-12-31 | Rp-259.46 | Rp126.00 | x |
| 2024-12-31 | Rp-369.13 | Rp126.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Indofarma Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -158.99%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-18.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 37.70% | 22.35% | 0.92x | 1.84x | Rp81.03 Billion |
| 2001 | 23.99% | 19.91% | 0.76x | 1.59x | Rp71.46 Billion |
| 2004 | 2.83% | 1.05% | 1.32x | 2.05x | Rp-18.33 Billion |
| 2005 | 3.62% | 1.40% | 1.32x | 1.96x | Rp-16.93 Billion |
| 2006 | 5.43% | 1.48% | 1.49x | 2.45x | Rp-12.81 Billion |
| 2007 | 3.80% | 0.87% | 1.26x | 3.46x | Rp-18.08 Billion |
| 2008 | 1.70% | 0.34% | 1.53x | 3.26x | Rp-24.63 Billion |
| 2009 | 0.71% | 0.19% | 1.55x | 2.44x | Rp-27.75 Billion |
| 2010 | 4.03% | 1.20% | 1.43x | 2.36x | Rp-18.58 Billion |
| 2011 | 6.06% | 3.07% | 1.08x | 1.83x | Rp-24.00 Billion |
| 2012 | 6.52% | 3.67% | 0.97x | 1.83x | Rp-22.63 Billion |
| 2013 | -9.18% | -4.05% | 1.03x | 2.19x | Rp-113.30 Billion |
| 2014 | 0.20% | 0.08% | 1.11x | 2.11x | Rp-58.03 Billion |
| 2015 | 1.11% | 0.40% | 1.06x | 2.59x | Rp-52.70 Billion |
| 2016 | -3.02% | -1.04% | 1.21x | 2.40x | Rp-74.94 Billion |
| 2017 | -8.79% | -2.84% | 1.07x | 2.91x | Rp-98.92 Billion |
| 2018 | -6.59% | -2.06% | 1.10x | 2.90x | Rp-82.40 Billion |
| 2019 | 1.58% | 0.59% | 0.98x | 2.74x | Rp-42.53 Billion |
| 2020 | 0.01% | 0.00% | 1.00x | 3.98x | Rp-43.00 Billion |
| 2021 | -7.39% | -1.29% | 1.44x | 3.96x | Rp-88.40 Billion |
| 2022 | -496.17% | -37.45% | 0.75x | 17.76x | Rp-437.12 Billion |
| 2023 | 0.00% | -137.70% | 0.69x | 0.00x | Rp-640.58 Billion |
| 2024 | 0.00% | -158.99% | 0.34x | 0.00x | Rp-220.09 Billion |
Industry Comparison
This section compares Indofarma Tbk's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,350,814,641,398
- Average return on equity (ROE) among peers: 17.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Indofarma Tbk (INAF) | Rp-890.94 Billion | 37.70% | N/A | $4.64 Million |
| Darya-Varia Laboratoria Tbk (DVLA) | $1.20 Trillion | 16.72% | 0.40x | $8.73 Million |
| Merck Tbk (MERK) | $416.74 Billion | 25.87% | 0.37x | $11.43 Million |
| Phapros Tbk PT (PEHA) | $821.61 Billion | 12.42% | 1.55x | $4.70 Million |
| Pyridam Farma Tbk (PYFA) | $118.93 Billion | 7.10% | 0.57x | $76.03 Million |
| Sido Muncul PT (SIDO) | $2.90 Trillion | 22.87% | 0.15x | $192.60 Million |
| Tempo Scan Pacific Tbk (TSPC) | $2.64 Trillion | 18.49% | 0.36x | $70.32 Million |